Anti-IL-36R antibodies for the treatment of pyoderma gangrenosum
US12098207B2 · kind B2 · utility
0Cited by
10References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 2021 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Apr 28, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for treating, preventing or ameliorating a neutrophilic dermatosis. The methods of the present invention include administering to a patient suffering from a neutrophilic dermatosis a pharmaceutical composition including an anti-interleukin-36 receptor (anti-IL-36R) antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.